{"prompt": "['APPENDIX 8: ASSESSMENT OF TOXICITIES', 'ASSESSMENT OF TOXICITIES NCI-CTC V4.0', 'http://evs.nci.nih.gov/ftpl/CTCAE/About.html', 'and then click \" Files Data \" on \" CTCAE 4.03 2010-06-14.xls \"', 'TOXICITY MANAGEMENT GUIDELINES', 'This document describing the management of toxicity related to immunotherapy is provided hereinafter. Each new updated', 'version will be provided by the sponsor to the center.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 89 de 123']['Dosing Modification and Toxicity Management Guidelines for Immune-Mediated, Infusion-Related, and', 'Non-Immune-Mediated Reactions (MEDI4736 Monotherapy or Combination Therapy With Tremelimumab or Tremelimumab', 'Monotherapy) 1 November 2017 Version', 'General Considerations', 'Dose Modifications', 'Toxicity Management', 'Drug administration modifications of study drug/study regimen will be made to manage potential', 'It is recommended that management of immune-mediated adverse events (imAEs) follows the', 'guidelines presented in this table:', 'immune-related AEs based on severity of treatment-emergent toxicities graded per NCI CTCAE v4.03.', '-', 'It is possible that events with an inflammatory or immune mediated mechanism could', 'In addition to the criteria for permanent discontinuation of study drug/study regimen based on CTC', 'occur in nearly all organs, some of them not noted specifically in these guidelines.', '-', 'grade/severity (table below), permanently discontinue study drug/study regimen for the following', 'Whether specific immune-mediated events (and/or laboratory indicators of such', 'events) are noted in these guidelines or not, patients should be thoroughly evaluated to', 'conditions:', 'rule out any alternative etiology (e.g., disease progression, concomitant medications,', 'Inability to reduce corticosteroid to a dose of <10 mg of prednisone per day (or equivalent)', 'and infections) to a possible immune-mediated event. In the absence of a clear', 'within 12 weeks after last dose of study drug/study regimen', 'alternative etiology, all such events should be managed as if they were immune', 'Recurrence of a previously experienced Grade 3 treatment-related AE following resumption of', 'related. General recommendations follow.', 'dosing', '-', 'Symptomatic and topical therapy should be considered for low-grade (Grade 1 or 2,', 'Grade 1', 'No dose modification', 'unless otherwise specified) events.', '-', 'For persistent (>3 to 5 days) low-grade (Grade : 2) or severe (Grade: 3) events,', 'Grade 2', 'Hold study drug/study regimen dose until Grade 2 resolution to Grade 1.', 'promptly start prednisone 1 to 2 mg/kg/day PO or IV equivalent.', 'If toxicity worsens, then treat as Grade 3 or Grade 4.', '-', 'Some events with high likelihood for morbidity and/or mortality - e.g., myo-carditis,', 'or other similar events even if they are not currently noted in the guidelines - should', 'Study drug/study regimen can be resumed once event stabilizes to Grade 1 after', 'progress rapidly to high dose IV corticosteroids (methylprednisolone at 2 to', 'completion of steroid taper.', '4 mg/kg/day) even if the event is Grade 2, and if clinical suspicion is high and/or there', 'Patients with endocrinopathies who may require prolonged or continued steroid', 'has been clinical confirmation. Consider, as necessary, discussing with the study', 'physician, and promptly pursue specialist consultation.', 'replacement can be retreated with study drug/study regimen on the following conditions:', '-', 'If symptoms recur or worsen during corticosteroid tapering (28 days of taper), increase', '1.', 'The event stabilizes and is controlled.', 'the corticosteroid dose (prednisone dose [e.g., up to 2 to 4 mg/kg/day PO or IV', '2.', \"The patient is clinically stable as per Investigator or treating physician's clinical\", 'equivalent]) until stabilization or improvement of symptoms, then resume', 'judgement.', 'corticosteroid tapering at a slower rate (>28 days of taper).', '3.', 'Doses of prednisone are at 10 mg/day or equivalent.', '-', 'More potent immunosuppressives such as TNF inhibitors (e.g., infliximab) (also refer', 'Grade 3', 'Depending on the individual toxicity, study drug/study regimen may be permanently', 'to the individual sections of the imAEs for specific type of immunosuppressive)', 'should be considered for events not responding to systemic steroids. Progression to use', 'discontinued. Please refer to guidelines below.', 'of more potent immunosuppressives should proceed more rapidly in events with high', 'Grade 4', 'Permanently discontinue study drug/study regimen.', 'likelihood for morbidity and/or mortality - e.g., myocarditis, or other similar events', 'Note: For Grade 3 asymptomatic amylase or lipase levels, hold study drug/study regimen, and if', 'even if they are not currently noted in the guidelines - when these events are not', 'responding to systemic steroids.', 'complete work up shows no evidence of pancreatitis, study drug/study regimen may be continued or', '-', 'With long-term steroid and other immunosuppressive use, consider need for', 'resumed.', 'Pneumocystis jirovecii pneumonia (PJP, formerly known as Pneumocystis carinii', 'Note: Study drug/study regimen should be permanently discontinued in Grade 3 events with high', 'pneumonia) prophylaxis, gastrointestinal protection, and glucose monitoring.', '-', 'Discontinuation of study drug/study regimen is not mandated for Grade 3/Grade 4', 'likelihood for morbidity and/or mortality - e.g., myocarditis, or other similar events even if they are not', 'inflammatory reactions attributed to local tumor response (e.g., inflammatory reaction', 'currently noted in the guidelines. Similarly, consider whether study drug/study regimen should be', 'at sites of metastatic disease and lymph nodes). Continuation of study drug/study', 'regimen in this situation should be based upon a benefit-risk analysis for that patient.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 90 de 123']\n\n###\n\n", "completion": "END"}